CITRUPRESS
IV


CITRUPRESS IV (IV Citrulline)
OVERVIEW:

Seven potential indications

Four are prophylactic

Total market size for the first three indications is 650,000 patients (US only)

Sales: First three indications: $500MM+

Citrupress IV appears to be one of those classic small indication/ broad application products not unlike Botox, a drug that was initially approved for treatment of blepharospasm, but now has eight approved indications and more indications in process.


IV CITRUPRESS:

Phase III Clinical Trial for Prophylaxis of Post Congenital Heart Repair By-Pass Surgery

Phase I/II for Status Asthmaticus and Bronchopulmonary Dysplasia

Initial Commercialization in 2010

Excellent Toxicity and Safety Profile

Significant Off-label Use Anticipated

Sound Intellectual Property

Good Manufacturing and Proprietary Processes

Targeted Hospital Sales and Marketing

Citrupress IV has the versatility to serve multiple markets for which there are significant unmet medical needs. Citrulline is an amino acid that is a key component of the urea cycle in the liver for which it acts as a substrate in the production of l-Arginine, the direct precursor for nitric oxide production. By increasing the liver concentration of citrulline a cascade of metabolic event ensues resulting in a targeted therapeutic bronchodilation and vasodilation effect. Approximately 40,000 children are born each year in the United States with congenital heart defects, of these, a large majority will require congenital heart repair surgery. This is the targeted market for prophylaxis of pulmonary hypertension in post cardiac surgery patients.


Click here for the Detailed Market Potential Chart.

Click here for the Highly Efficient Market Reach and Frequency Chart.

Click here for the Urea Cycle.


Back to Top